Printer Friendly

HARRIER SPONSORS PHARMACEUTICAL RESEARCH PROJECT AT U. OF MICHIGAN; ENTERS SEPARATE AGREEMENT TO FUND BIOCHEMICAL DEVELOPMENT ACTIVITY

    HARRIER SPONSORS PHARMACEUTICAL RESEARCH PROJECT AT U. OF MICHIGAN;
    ENTERS SEPARATE AGREEMENT TO FUND BIOCHEMICAL DEVELOPMENT ACTIVITY
    LOS ANGELES, Nov. 12 /PRNewswire/ -- Harrier, Inc. (NASDAQ: HARE), today announced that it had entered into a two-year research agreement with the University of Michigan under which the institution's Department of Chemistry would explore the company's proprietary Klemke Method(TM), determine its mechanism and examine its general applicability in the glycosylation of a number of chemical products and pharmaceuticals.
    Glycosylation, a chemical reaction by which a carbohydrate is attached to an organic molecule, is a subject of intense current interest among practicing organic and medicinal chemists.  According to the company, the Klemke Method is a process by which such a reaction is produced more mildly, effectively and at lower cost than currently available processes.
    In the event that patent applications are made involving products developed jointly with or solely by employees of the university, the agreement calls for Harrier to be granted, at its option, an exclusive or non-exclusive royalty-bearing license.
    In a separate agreement, Harrier and the Techno-Bio subsidiary of SECOM Co., Ltd., of Tokyo entered into a joint research and development contract relating to Harrier's biochemical product line.  According to Harrier, the cooperative effort will further the development of Harrier's Tumosterone pharmaceutical as an anti-cancer drug, develop new applications for the Klemke Method, obtain patent protection and execute licenses to third parties with respect to current and future products that result from the application of this technology.  The agreement calls for Techno-Bio to fund current R&D programs under way at the University of Michigan and the Cancer Therapy and Research Center in San Antonio, Texas, and to finance patent costs and a certain portion of Harrier's R&D overhead expenditures in return for a sharing of future royalty income.
    SECOM Co., Ltd., is a diversified multinational company which, by virtue of its purchase of Harrier's convertible preferred shares approximately two years ago, is a large stockholder of the company. Harrier, Inc., is primarily engaged in the development and commercialization of unique technologies in the health and environmental fields.
    -0-                     11/12/91
    /CONTACT:  Kevin DeVito, VP-U.S. operations of Harrier, 213-376-7721/
    (HARE) CO:  Harrier, Inc.; SECOM Co., Ltd. ST:  California, Michigan IN:  MTC CHM SU: GK-CK -- NY026 -- 3371 11/12/91 10:32 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 12, 1991
Words:384
Previous Article:SPOKANE, WASH. WATER REVENUE BOND RATING UPGRADED FROM
Next Article:SEARS ANNOUNCES
Topics:


Related Articles
SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
HARRIER FILES GLYCOSYLATION PATENT APPLICATIONS
HARRIER ESTABLISHES BIOCHEMICAL SUBSIDIARY
RIBOZYME PHARMACEUTICALS AND PARKE-DAVIS PHARMACEUTICAL RESEARCH ENTER INTO RESEARCH AND DEVELOPMENT COLLABORATION
STI LICENSES NEW PAIN PRODUCT TO LOTUS FOR HOME HEALTH CARE
HARRIER TERMINATES AGREEMENT WITH AMERICAN DIAGNOSTICA INC.
MITOTIX AND THE DUPONT MERCK PHARMACEUTICAL COMPANY SIGN AGREEMENT TO DEVELOP CELL CYCLE-BASED DRUGS TO TREAT CANCER
SmithKline Beecham and Ligand Add Leptin-Obesity Research to Existing Collaboration
Antigenics Establishes Autologous Cancer Vaccine Collaboration With Sigma-Tau; Sigma-Tau to Partake in Clinical Trials in Italy Using HSP-Based...
Pharmagene and Argenta enter new alliances.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters